Profusa Launches Lumee Monitoring System Targeting $47.9 Billion CRO Market

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: 21 Jan 26

Source: Globenewswire

Profusa Inc's stock surged by 26.18% as it crossed above the 5-day SMA, reflecting strong investor interest following the launch of its Lumee tissue oxygen monitoring system.

The launch of the Lumee system is strategically aimed at the contract research organization (CRO) market, projected to generate immediate service revenue in a $47.9 billion global market. This innovative platform enables continuous measurement of tissue oxygen levels, addressing the demand for real-time biological data and enhancing drug development efficiency. Additionally, Profusa appointed Sean Givens as Head of Government and Healthcare Research Business to drive commercialization efforts, further solidifying the company's position in the biotech sector.

This significant market opportunity not only opens new revenue streams for Profusa but also positions the company favorably within a rapidly growing industry, as the global pharmaceutical CRO market is expected to expand significantly in the coming years.

PFSA

$0.1044+Infinity%1D

Analyst Views on PFSA

About PFSA

Profusa, Inc. is a commercial stage digital health company. The Company is engaged in the development of a new generation of biointegrated sensors that potentially empower the individual with the ability to monitor their body chemistry. The Company’s technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. Its first clinical offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels in various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds (diabetic ulcers, pressure sores) that do not heal properly; and reconstructive surgery.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Profusa Launches Lumee Monitoring System Targeting $47.9 Billion CRO Market

Analyst Views on PFSA

About PFSA

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Altimmune Secures $75M from Institutional Investor in Direct Offering

American Bitcoin Increases Reserves to 5,843 BTC

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch